Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026
21 patents granted to the 3 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to AnaptysBio, Inc.’s names, not what it holds today.
Patents granted
21
21 utility, 1976 to Dec 31, 2025
Granted in 2025
1
Against 1 in 2024 and 1 in 2023
Applications published
49
2 of them in 2025
Names they are printed under
3
its own name, a former name
By yearGrantedApplications published
'11'12'13'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals5
Biotechnology1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name3 counted
ANAPTYSBIO, INC. its own name
US, as the owner printed on each patent
21 publishedAnaptysBio, Inc. its own name
named as the applicant on its applications, in US
27 publishedANAPTYS BIOSCIENCES, INC. a former name
US, as the owner printed on each patent
1 published
Newest grantseach row opens the USPTO’s own copy
| Granted | Patent | Title | Field | Owner as printed |
|---|
| Aug 19, 2025 | 12,391,761 | Antibodies directed against interleukin 36 receptor (IL-36R) | Pharmaceuticals | ANAPTYSBIO, INC. |
| Jun 4, 2024 | 11,999,783 | Method of treating autoimmune disease with antibodies against IL-33 | Pharmaceuticals | ANAPTYSBIO, INC. |
| Sep 12, 2023 | 11,753,472 | Antibodies directed against T cell immunoglobulin and mucin protein 3 (TIM-3) | Pharmaceuticals | ANAPTYSBIO, INC. |
| Jun 7, 2022 | 11,352,427 | Antibodies directed against T Cell immunoglobulin and mucin protein 3 (TIM-3) | Biotechnology | ANAPTYSBIO, INC. |
| Oct 26, 2021 | 11,155,624 | Antibodies directed against programmed death-1 (PD-1) | Pharmaceuticals | ANAPTYSBIO, INC. |
| Sep 28, 2021 | 11,130,814 | Method of treating pustular psoriasis with antibodies directed against interleukin 36 receptor (IL-36R) | Pharmaceuticals | ANAPTYSBIO, INC. |
| Nov 17, 2020 | 10,836,824 | Antibodies directed against lymphocyte activation gene 3 (LAG-3) | Pharmaceuticals | ANAPTYSBIO, INC. |
| Nov 17, 2020 | 10,836,820 | Method of treating inflammatory disorder with antibodies directed against interleukin-33 (IL-33) | Pharmaceuticals | ANAPTYSBIO, INC. |
| Aug 11, 2020 | 10,738,117 | Antibodies directed against programmed death-1 (PD-1) | Pharmaceuticals | ANAPTYSBIO, INC. |
| Jan 7, 2020 | 10,526,410 | Antibodies directed against interleukin 36 receptor (IL-36R) | Pharmaceuticals | ANAPTYSBIO, INC. |
Newest applications publishedan application is a clue, never a plan
| Published | Application | Title | Field | Owner as printed |
|---|
| Dec 4, 2025 | 2025/0368739 | Antibodies Directed Against T Cell Immunoglobulin and Mucin Protein 3 (TIM-3) | Pharmaceuticals | ANAPTYSBIO, INC. |
| Sep 11, 2025 | 2025/0282872 | B AND T LYMPHOCYTE ATTENUATOR (BTLA) MODULATORS AND METHOD OF USING SAME | Pharmaceuticals | AnaptysBio, Inc. |
| Sep 5, 2024 | 2024/0294631 | ANTIBODIES DIRECTED AGAINST INTERLEUKIN-33 (IL-33) | Pharmaceuticals | AnaptysBio, Inc. |
| Jul 4, 2024 | 2024/0216506 | ANTIBODY COMPOSITION | Pharmaceuticals | AnaptysBio, Inc. |
| May 16, 2024 | 2024/0158495 | Antibody Agents Directed Against Lymphocyte Activation Gene-3 (LAG-3) and Uses Thereof | Pharmaceuticals | AnaptysBio, Inc. |
| Mar 14, 2024 | 2024/0084021 | ANTI-INTERLEUKIN 36 RECEPTOR (IL-36R) THERAPY FOR HIDRADENITIS SUPPURATIVA | Pharmaceuticals | AnaptysBio, Inc. |
| Dec 28, 2023 | 2023/0416368 | Antibodies Directed Against T Cell Immunoglobulin and Mucin Protein 3 (TIM-3) | Pharmaceuticals | AnaptysBio, Inc. |
| Dec 7, 2023 | 2023/0391872 | B AND T LYMPHOCYTE ATTENUATOR (BTLA) MODULATORS AND METHOD OF USING SAME | Pharmaceuticals | AnaptysBio, Inc. |
| Oct 19, 2023 | 2023/0331843 | Antibodies Directed Against Programmed Death-1(PD-1) | Pharmaceuticals | AnaptysBio, Inc. |
| Aug 31, 2023 | 2023/0272092 | ANTI-INTERLEUKIN 36 RECEPTOR (IL-36R) THERAPY FOR ICHTHYOSIS | Pharmaceuticals | AnaptysBio, Inc. |
What it applied for, 2024 to 2025: Pharmaceuticals 6.
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.